7CJT
Crystal Structure of SETDB1 Tudor domain in complexed with (R,R)-59
Summary for 7CJT
Entry DOI | 10.2210/pdb7cjt/pdb |
Descriptor | Histone-lysine N-methyltransferase SETDB1, 2-[[(3~{R},5~{R})-1-methyl-5-(4-phenylmethoxyphenyl)piperidin-3-yl]amino]-3-prop-2-enyl-5~{H}-pyrrolo[3,2-d]pyrimidin-4-one (3 entities in total) |
Functional Keywords | setdb1, tudor domian, inhibitor, transferase |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 4 |
Total formula weight | 112332.52 |
Authors | |
Primary citation | Guo, Y.,Mao, X.,Xiong, L.,Xia, A.,You, J.,Lin, G.,Wu, C.,Huang, L.,Wang, Y.,Yang, S. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain. Angew.Chem.Int.Ed.Engl., 60:8760-8765, 2021 Cited by PubMed Abstract: SET domain bifurcated protein 1 (SETDB1) is a histone lysine methyltransferase that promotes the silencing of some tumour suppressor genes and is overexpressed in many cancers. SETDB1 contains a unique tandem tudor domain (TTD) that recognizes histone H3 sequences containing both methylated and acetylated lysines. Beginning with the identification of a hit compound (Cpd1), we discovered the first potent and selective small molecule SETDB1-TTD inhibitor (R,R)-59 through stepwise structure-guided optimization. (R,R)-59 showed a K value of 0.088±0.045 μM in the ITC assay. The high potency of (R,R)-59 was well explained by the cocrystal structure of the (R,R)-59-TTD complex. (R,R)-59 is an endogenous binder competitive inhibitor. Evidence has also demonstrated its cellular target engagement. Interestingly, the enantiomer (S,S)-59 did not show activity in all the assays, highlighting the potential of (R,R)-59 as a tool compound in exploring the biological functions of SETDB1-TTD. PubMed: 33511756DOI: 10.1002/anie.202017200 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.474 Å) |
Structure validation
Download full validation report